Published mark
ANAVEX LIFE SCIENCES CORP.
NASDAQ: AVXL. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:121f7b6f-a4b4-45f7-98f2-23c1a8e32884
- SEC CIK
- 0001314052
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 19, 2026
- Newest evidence
- Nov 25, 2025
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Christopher MisslingSince Nov 25, 2025
- Chair
- Not published
- Independent
- 5 / 66 directors published
- Published claims
- 243 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Christopher Missling executive of ANAVEX LIFE SCIENCES CORP., effective 2025-11-25.
EffectiveEffective Nov 25, 2025E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Executive Officer (Principal Executive Officer) and Director | Christopher Missling | Nov 2025 | current | Source reportedE3 |
| Principal Financial Officer and Treasurer (Principal Accounting Officer) | Sandra Boenisch | Nov 2025 | current | Source reportedE4 |
Board of directors
Evidence6 directors published. 5 of 6 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Athanasios Skarpelos | Independent | 2013 | None published | Source reportedE2 |
| Christopher Missling, PhD | Not independent | 2013 | None published | Source reportedE2 |
| Claus van der Velden, PhD | Independent | 2018 | Audit, chairAudit · Chair; Compensation · Chair; Nominating and Governance · ChairCompensation, chairNominating and Governance, chair | Source reportedE2 |
| Jiong Ma, PhD | Independent | 2021 | AuditAudit; Compensation · Chair; Nominating and GovernanceCompensation, chairNominating and Governance | Source reportedE2 |
| Peter Donhauser, D.O. | Independent | 2017 | None published | Source reportedE2 |
| Steffen Thomas, PhD | Independent | 2015 | AuditAudit; Compensation; Nominating and GovernanceCompensationNominating and Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Claus van der Velden, PhD | Claus van der Velden, PhD, Jiong Ma, PhD, Steffen Thomas, PhD | Not described in the published record |
| Audit · Chair; Compensation · Chair; Nominating and Governance · Chair | Not published | Claus van der Velden, PhD | Not described in the published record |
| Audit; Compensation · Chair; Nominating and Governance | Not published | Jiong Ma, PhD | Not described in the published record |
| Audit; Compensation; Nominating and Governance | Not published | Steffen Thomas, PhD | Not described in the published record |
| Compensation | Jiong Ma, PhD | Claus van der Velden, PhD, Jiong Ma, PhD, Steffen Thomas, PhD | Not described in the published record |
| Nominating and Governance | Claus van der Velden, PhD | Claus van der Velden, PhD, Jiong Ma, PhD, Steffen Thomas, PhD | Not described in the published record |
Committee RecordAudit: Chair Claus van der Velden, PhD; Members Claus van der Velden, PhD (Chair); Jiong Ma, PhD; Steffen Thomas, PhD
Committee AppointmentClaus van der Velden, PhD: chair, Audit
Committee AppointmentJiong Ma, PhD: member, Audit
Committee AppointmentSteffen Thomas, PhD: member, Audit
Committee RecordCompensation: Chair Claus van der Velden, PhD; Jiong Ma, PhD; Members Claus van der Velden, PhD (Chair); Jiong Ma, PhD (Chair); Steffen Thomas, PhD
Committee AppointmentClaus van der Velden, PhD: chair, Compensation
Committee AppointmentJiong Ma, PhD: chair, Compensation
Committee AppointmentSteffen Thomas, PhD: member, Compensation
Committee RecordNominating and Governance: Chair Claus van der Velden, PhD; Members Claus van der Velden, PhD (Chair); Jiong Ma, PhD; Steffen Thomas, PhD
Committee AppointmentClaus van der Velden, PhD: chair, Nominating and Governance
Committee AppointmentJiong Ma, PhD: member, Nominating and Governance
Committee AppointmentSteffen Thomas, PhD: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerChristopher Missling, Chief Executive Officer (Principal Executive Officer) and Director, from Nov 25, 2025
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingAVXL (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 20, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameANAVEX LIFE SCIENCES CORP.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Christopher MisslingChief Executive Officer (Principal Executive Officer) and Directorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:11
- Sandra BoenischPrincipal Financial Officer and Treasurer (Principal Accounting Officer)company:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:12
- Athanasios SkarpelosDirectorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:5
- Christopher Missling, PhDDirectorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:6
- Claus van der Velden, PhDDirectorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:7
- Jiong Ma, PhDDirectorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:8
- Peter Donhauser, D.O.Directorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:9
- Steffen Thomas, PhDDirectorcompany:121f7b6f-a4b4-45f7-98f2-23c1a8e32884:leadership_role:10
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 19, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 25, 2025. Retrieved Apr 24, 2026. Cited by 6 Claims.
- E3sec filing. Published Nov 25, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E4sec filing. Published Nov 25, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E5board_seats. board seats. Cited by 12 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 19, 2026- Christopher Missling executive of ANAVEX LIFE SCIENCES CORP., effective 2025-11-25.
- Sandra Boenisch executive of ANAVEX LIFE SCIENCES CORP., effective 2025-11-25.
- Jiong Ma, PhD seat on ANAVEX LIFE SCIENCES CORP., effective 2021-01-01.
- Audit; Compensation · Chair; Nominating and Governance committee of ANAVEX LIFE SCIENCES CORP., effective 2021-01-01.
- Jiong Ma, PhD member of Audit; Compensation · Chair; Nominating and Governance, effective 2021-01-01.
- Claus van der Velden, PhD seat on ANAVEX LIFE SCIENCES CORP., effective 2018-01-01.
- Audit · Chair; Compensation · Chair; Nominating and Governance · Chair committee of ANAVEX LIFE SCIENCES CORP., effective 2018-01-01.
- Claus van der Velden, PhD member of Audit · Chair; Compensation · Chair; Nominating and Governance · Chair, effective 2018-01-01.
- Peter Donhauser, D.O. seat on ANAVEX LIFE SCIENCES CORP., effective 2017-01-01.
- Steffen Thomas, PhD seat on ANAVEX LIFE SCIENCES CORP., effective 2015-01-01.
- Audit; Compensation; Nominating and Governance committee of ANAVEX LIFE SCIENCES CORP., effective 2015-01-01.
- Steffen Thomas, PhD member of Audit; Compensation; Nominating and Governance, effective 2015-01-01.
- Athanasios Skarpelos seat on ANAVEX LIFE SCIENCES CORP., effective 2013-01-01.
- Christopher Missling, PhD seat on ANAVEX LIFE SCIENCES CORP., effective 2013-01-01.